GoodRx (NASDAQ:GDRX) Releases Earnings Results, Hits Estimates

GoodRx (NASDAQ:GDRX) posted its earnings results on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09, FiscalAI reports. The business had revenue of $194.79 million for the quarter, compared to analysts’ expectations of $193.27 million. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.The business’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.09 earnings per share.

GoodRx Trading Down 2.7%

GDRX opened at $2.17 on Thursday. GoodRx has a 12-month low of $1.77 and a 12-month high of $5.81. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.61 and a quick ratio of 2.61. The stock has a market capitalization of $736.56 million, a PE ratio of 24.11, a P/E/G ratio of 1.54 and a beta of 1.52. The firm’s fifty day moving average price is $2.37 and its 200 day moving average price is $3.07.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on GDRX shares. Jefferies Financial Group cut GoodRx to a “hold” rating in a research report on Thursday, January 22nd. Wells Fargo & Company reduced their price target on shares of GoodRx from $7.00 to $3.50 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Barclays assumed coverage on shares of GoodRx in a research note on Monday, December 8th. They set an “underweight” rating and a $3.00 price objective for the company. Citigroup cut their target price on shares of GoodRx from $4.50 to $3.50 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Finally, Bank of America reiterated a “reduce” rating on shares of GoodRx in a report on Monday, January 5th. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, GoodRx has a consensus rating of “Hold” and an average price target of $3.98.

Institutional Investors Weigh In On GoodRx

Institutional investors and hedge funds have recently made changes to their positions in the company. Quarry LP acquired a new stake in GoodRx during the third quarter worth about $33,000. MML Investors Services LLC acquired a new position in GoodRx in the fourth quarter valued at approximately $36,000. DRW Securities LLC acquired a new position in GoodRx in the fourth quarter valued at approximately $40,000. Boothbay Fund Management LLC bought a new position in shares of GoodRx during the third quarter valued at approximately $43,000. Finally, EP Wealth Advisors LLC bought a new position in shares of GoodRx during the fourth quarter valued at approximately $44,000. 63.77% of the stock is owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.